- Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits ("NIHB") program of Indigenous Services Canada and Veteran Affairs Canada ("VAC")
- Public reimbursement now includes Ontario, Quebec, Alberta, Manitoba, Nova Scotia, New Brunswick, NIHB and VAC covering over 80% of the Canadian population
- Private insurance coverage across Canada exceeds 90%
MONTREAL, Feb. 24, 2022 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is proud to announce another major milestone for its two innovative Asthma therapies; Enerzair Breezehaler and Atectura Breezhaler, which have been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the NIHB and VAC federal programs. The public reimbursments are now in effect with the exception of the Ontario listing which takes effect on February 28th, 2022. These listings are now published on the Ontario Drug Benefit Formulary, the Manitoba Drug Benefits Formulary and New Brunswick Drug Plans Formulary.
"With the addition of Ontario, Manitoba, New Brunswick, NIHB and VAC to our exisiting list of provincial/federal public listings, public reimbursement now covers over 80% of the Canadian population suffering from chronic asthma thereby improving their access to these two innovative medications", said Frederic Fasano, Valeo's President and Chief Operating Officer. "Securing extensive public and private reimbursment was part of our roadmap to build a fast-growing respiratory business unit. We are now working with the remaining provincial authorities to secure their public reimbursement in order to continue making asthma control a more attainable goal for all Canadians asthma patients".
Public coverage in these jurisdictions also means that private payers that follow public plans will now cover both drugs. Private coverage for Enerzair and Atectura now exceeds 90% of privately covered lives accross Canada.